Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.96 [0.64, 1.43]
1 study · 215 participants
Low